Patients | Total (n = 298) | First recurrence (n = 50) | Second recurrence (n = 6) | Death (n = 21)* |
---|---|---|---|---|
Histology | ||||
 Lobular | 229 | 38 | 3 | 14 |
 Pleomorphic | 31 | 8 | 2 | 6 |
 Mixed | 38 | 4 | 1 | 1 |
Focality | ||||
 Unifocal | 122 | 17 | 1 | 10 |
 Bifocal/multifocal | 175 | 33 | 5 | 10 |
 Unknown | 1 | 0 | 0 | 1 |
Tumor diameter | ||||
 2–19 mm | 212 | 35 | 3 | 8 |
 20–49 mm | 71 | 8 | 1 | 7 |
 > 50 mm | 15 | 7 | 2 | 6 |
Axillary load | ||||
 None | 192 | 26 | 3 | 7 |
 1–3 | 84 | 13 | 1 | 3 |
 > 4 | 21 | 11 | 2 | 10 |
 Unknown | 1 | 0 | 0 | 1 |
Hormone receptor | ||||
 ER/PR+ HER2− | 292 | 49 | 6 | 21 |
 HER2+ | 6 | 1 | 0 | 0 |
Endocrine treatment | ||||
 AI | 139 | 19 | 3 | 10 |
 SERMS | 156 | 31 | 3 | 11 |
 LHRH analogues | 3 |  |  |  |
Endocrine treatment duration | ||||
 ≤ 5 years | 145 | 32 | 4 | 16 |
 ≥ 6 years | 153 | 18 | 2 | 5 |
Concurrent chemotherapy and radiotherapy | ||||
 Chemotherapy | 193 | 38 | 5 | 19 |
 Radiotherapy | 200 | 36 | 5 | 14 |
 Chemo + radio | 126 | 28 | 4 | 12 |
 No chemo-/radiotherapy | 31 | 4 | 0 | 0 |